↓ Skip to main content

Cochrane Database of Systematic Reviews

Buprenorphine for neuropathic pain in adults

Overview of attention for article published in Cochrane database of systematic reviews, September 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

blogs
1 blog
policy
1 policy source
twitter
16 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
149 Mendeley
Title
Buprenorphine for neuropathic pain in adults
Published in
Cochrane database of systematic reviews, September 2015
DOI 10.1002/14651858.cd011603.pub2
Pubmed ID
Authors

Philip J Wiffen, Sheena Derry, R Andrew Moore, Cathy Stannard, Dominic Aldington, Peter Cole, Roger Knaggs

Abstract

Opioid drugs, including buprenorphine, are commonly used to treat neuropathic pain, and are considered effective by some professionals. Most reviews have examined all opioids together. This review sought evidence specifically for buprenorphine, at any dose, and by any route of administration. Other opioids are considered in separate reviews. To assess the analgesic efficacy of buprenorphine for chronic neuropathic pain in adults, and the adverse events associated with its use in clinical trials. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE from inception to 11 June 2015, together with reference lists of retrieved papers and reviews, and two online study registries. We included randomised, double-blind studies of two weeks' duration or longer, comparing any oral dose or formulation of buprenorphine with placebo or another active treatment in chronic neuropathic pain. Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any pooled analyses. Searches identified 10 published studies, and one study with results in ClinicalTrials.gov. None of these 11 studies satisfied our inclusion criteria, and so we included no studies in the review. There was insufficient evidence to support or refute the suggestion that buprenorphine has any efficacy in any neuropathic pain condition.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 149 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Colombia 1 <1%
Unknown 147 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 32 21%
Student > Bachelor 18 12%
Student > Ph. D. Student 17 11%
Researcher 13 9%
Student > Doctoral Student 11 7%
Other 18 12%
Unknown 40 27%
Readers by discipline Count As %
Medicine and Dentistry 54 36%
Nursing and Health Professions 19 13%
Psychology 9 6%
Agricultural and Biological Sciences 4 3%
Social Sciences 4 3%
Other 14 9%
Unknown 45 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 April 2021.
All research outputs
#1,139,812
of 18,110,549 outputs
Outputs from Cochrane database of systematic reviews
#2,897
of 11,820 outputs
Outputs of similar age
#21,082
of 260,374 outputs
Outputs of similar age from Cochrane database of systematic reviews
#91
of 257 outputs
Altmetric has tracked 18,110,549 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,820 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.5. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 257 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.